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ABSTRACT
Background  Indocyanine green (ICG)-enhanced 
ﬂ  uorescence optical imaging (FOI) is an established 
technology for imaging of inﬂ  ammation in animal 
models. In experimental models of arthritis, FOI ﬁ  ndings 
corresponded to histologically proven synovitis. This is 
the ﬁ  rst comparative study of FOI with other imaging 
modalities in humans with arthritis.
Methods  252 FOI examinations (Xiralite system, 
mivenion GmbH, Berlin, Germany; ICG bolus of 0.1 mg/kg/
body weight, sequence of 360 images, one image per 
second) were compared with clinical examination (CE), 
ultrasonography (US) and MRI of patients with arthritis of 
the hands.
Results  In an FOI sequence, three phases could be 
distinguished (P1–P3). With MRI as reference, FOI had 
a sensitivity of 76% and a speciﬁ  city of 54%, while the 
speciﬁ  city of phase 1 was 94%. FOI had agreement 
rates up to 88% versus CE, 64% versus greyscale US, 
88% versus power Doppler US and 83% versus MRI, 
depending on the compared phase and parameter. FOI 
showed a higher rate of positive results compared to 
CE, US and MRI. In individual patients, FOI correlated 
signiﬁ  cantly (p<0.05) with disease activity (Disease 
Activity Score 28, r=0.41), US (r=0.40) and RAMRIS 
(Rheumatoid Arthritis MRI Score) (r=0.56). FOI was 
normal in 97.8% of joints of controls.
Conclusion  ICG-enhanced FOI is a new technology 
offering sensitive imaging detection of inﬂ  ammatory 
changes in subjects with arthritis. FOI was more sensitive 
than CE and had good agreement with CE, US in power 
Doppler mode and MRI, while showing more positive 
results than these. An adequate interpretation of an FOI 
sequence requires a separate evaluation of all phases. For 
the detection of synovitis and tenosynovitis, FOI appears 
to be as informative as 1.5 T MRI and US.
INTRODUCTION
With recent advances in the management of rheu-
matic diseases, imaging plays a major role in early 
diagnosis, estimation of prognosis and evaluation of 
therapeutic outcome. In rheumatoid arthritis (RA), 
treat-to-target strategies1 and the adequate use of 
disease-modifying drugs1 2 require sensitive instru-
ments that allow a valid detection of affected joints.
Careful clinical examination (CE) is a prereq-
uisite but may miss subclinical inﬂ  ammation  in 
early disease as well as in clinical remission under 
treatment.3–5 Conventional radiography is com-
monly used as an indicator of prognosis and rep-
resents the standard outcome measure of disease 
progression in clinical studies but is displaying the 
result of previous inﬂ   ammatory processes rather 
than presenting current disease activity. MRI is 
considered the gold standard for imaging of syn-
ovitis, and MRI bone marrow oedema has been 
shown to be the strongest independent predictor 
of radiographic progression in RA.6 7 However, 
broader usage of MRI in clinical routine settings 
may be restricted by workﬂ  ow considerations, cost 
and limited availability.
Ultrasonography (US) in greyscale mode (GSUS) 
and US in power Doppler mode (PDUS) have been 
demonstrated as valid tools for the assessment of 
synovitis and scoring of clinical activity in RA.8–10 In 
daily clinical practice, PDUS is more available than 
MRI and often used for fast and dynamic assess-
ment of joint inﬂ  ammation.11 However, apart from 
clinical studies, the examination procedure is usu-
ally limited to a reduced number of joints12 due to 
time constraints.
Fluorescence optical imaging (FOI) is an estab-
lished technology that has been evaluated for imag-
ing of inﬂ  ammation in a variety of animal models.13 
In experimental models of arthritis, indocyanine 
green (ICG)-enhanced FOI ﬁ  ndings corresponded 
to histologically proven synovitis.14 15 The feasibil-
ity of this approach in humans was tested,16 17 and 
an FOI system with ﬁ  xed optical geometry was 
developed (Xiralite X4; mivenion GmbH, Berlin, 
Germany).
We report the results of the ﬁ  rst  comparative 
study of this commercially available FOI system 
with CE, US and contrast-enhanced MRI in two 
major cohorts of patients with arthritis and allied 
conditions and controls.
PATIENTS AND METHODS
Patients
Two hundred and ﬁ  fty-two subjects with arthritis 
and allied conditions were recruited in two cen-
tres. One hundred and ﬁ  fty-three consecutive FOI 
examinations were evaluated in centre 1. Ninety-
nine outpatients were recruited randomly in centre 
2. Inclusion criteria were symptoms in the hands 
and agreement for participation in the study. Two 
patients did not want to participate in the study 
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Statistical analysis
Data evaluation and statistical analysis were performed using 
SAS 9.2 (SAS Institute, Cary, North Carolina, USA). Analyses 
were conducted at the patient and individual joint level. MRI, 
GSUS and PDUS were used as the standard reference method 
for calculation of sensitivity and speciﬁ  city. The agreement rates 
(ARs) between pairs of modalities (FOI, CE, US and MRI; swol-
len and tender joints, synovitis and tenosynovitis), sensitivities 
and speciﬁ  cities were calculated along with conﬁ  dence intervals 
on all joints with non-missing data using a modiﬁ  ed adjusted χ2 
test22 to cover correlations of multiple joints within the same 
patient. The AR was determined taking into consideration all 
joints that were affected (grades 1–3) or not affected (grade 0) 
in both modalities. Comparisons of AR of subgroups (RA, uA 
and PsA) were performed using appropriate contrasts within 
logistic regression models. For further analyses of efﬁ  cacy, sum-
mary statistics, frequency counts and 95% conﬁ  dence intervals 
were computed as appropriate. The correlations of the scores 
were calculated using Spearman’s rank correlation coefﬁ  cient. 
Statistical signiﬁ  cance was concluded with two-sided p values 
below 0.05.
RESULTS
Patients’ characteristics
The main clinical, laboratory, MRI and US characteristics are 
detailed in table 1.
Morphological FOI ﬁ  ndings
Analysing a single FOI sequence, we found that, within each 
image stack, three phases (P1–P3) may be distinguished as deﬁ  ned 
by the different time points’ increased signal intensities in the 
ﬁ  ngertips. Figure 2 shows a typical FOI image of highly active 
RA, displaying focal increased signal intensity in all three phases. 
Inﬂ  ammatory activity in a variety of affected structures was also 
detected in PsA (ﬁ  gure 3). A triangular, slightly arcuate enhance-
ment from nail bed into DIP was observed in 60 out of 64 (94%) 
subjects with PsA compared with 8 out of 38 (21%) in patients 
with deﬁ  nite RA (sensitivity 94%, speciﬁ  city 79%, positive pre-
dictive value 0.88, negative predictive value 0.88; subjects with 
both RA and psoriasis have been excluded from the calculation).
after detailed information. Six healthy individuals and six sub-
jects with arthralgia without any sign of an inﬂ  ammatory rheu-
matic disease served as the control group.
The study was performed in compliance with the Declaration 
of Helsinki. The study protocol was approved by the ethics 
committee of the Charité University Clinic Berlin. All study par-
ticipants had signed consent forms after receiving written and 
oral information.
Clinical and laboratory assessment
CE and laboratory tests (erythrocyte sedimentation rate (ESR) 
and C reactive protein (CRP)) were performed. Clinical swol-
len and tender joints (including distal interphalangeal joint 
(DIP)) were scored for presence and absence (0–1). The Disease 
Activity Score 28 (DAS28)18 was used to assess disease activity 
in patients with RA, psoriatic arthritis (PsA) and undifferentiated 
arthritis (uA).
Ultrasonography
Seventy-four subjects from centre 2 were examined by GSUS 
and PDUS (Mylab 70 XVG, Esaote, Genova, Italy). Nine hundred 
and sixty-two joints (wrist, metacarpophalangeal joint (MCP) 
2–5, proximal interphalangeal joint (PIP) 2–5 and DIP 2–5 of the 
clinically dominant hand) were evaluated semiquantitatively 
(grades 0–3) for synovitis and synovial/tenosynovial vascularity 
in a standardised manner.9 12 Tenosynovitis was scored for pres-
ence and absence (0–1). For individual patients, a US sum score 
over the evaluated joints was calculated.
Magnetic resonance imaging
Fat-saturated coronal proton-density (FS-PD-TSE), non-enhanced 
and enhanced T1-TSE with subtraction, coronal and axial fat-
saturated postintravenous gadolinium (Dotarem, 0.2 ml/kg/
body weight) (FS-T1-TSE) sequences of the clinically domi-
nant hand were performed in 25 patients (1.5 T MRI; Siemens 
Magnetom Symphony, Erlangen, Germany). MRI ﬁ  ndings (MCP 
1–5, interphalangeal joint ﬁ  nger 1 (IP), PIP 2–5, DIP 5 and wrist 
as a whole) were scored according to the OMERACT (Outcome 
Measures in Rheumatoid Arthritis Clinical Trials) criteria.19–21 
The RAMRI score was calculated.
Fluorescence optical imaging
Background of the technology and details of the Xiralite system 
(ﬁ  gure 1) are described in a supplementary text (only online avail-
able). The FOI examination follows a standardised procedure: 
both hands are placed on a preformed hand rest. Ten seconds after 
starting the examination, an ICG bolus is injected (ICG-Pulsion, 
0.1 mg/kg/body weight intravenously). The system acquires one 
image every second. Any alteration of ﬂ  uorophor  concentra-
tion can be depicted as alteration of signal intensity. In a pilot 
study, it was found that the signal enhancement had signiﬁ  cantly 
decreased after an examination period of 6 min. Therefore, this 
duration was determined as the standard examination time.
FOI ﬁ   ndings were analysed separately for an individual 
sequence of 360 images and an electronically generated com-
posite image (CI), automatically obtained by means of the 
integrated software XiraView (version 3.6). A semiquantitative 
score was applied for assessment of FOI ﬁ  ndings (0=no sig-
nal enhancement, 1=low (≤25%), 2=moderate (>25%, ≤50%), 
3=strong (>50% of affected joint area)). For individual patients, 
a sum score over all joints (DIP 2–5, PIP 2–5, IP, MCP 1–5, wrist 
and both hands; range 0–90) was calculated. All FOI ﬁ  ndings 
were analysed and reported by one reader.
Figure 1  Schematic display of the Xiralite system. A preformed hand 
rest is used for reliant positioning of both hands. High-power light-
emitting diodes (LEDs) illuminate the ﬁ  eld of view with dark red light, 
whereas a specialised digital camera system (charge-coupled device) 
records the ﬂ  uorescence signal intensities in the near-infrared spectrum.
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and RAMRIS synovitis (r=0.56, p<0.0001), weakly correlated 
with DAS28 (r=0.32, p<0.0001) and did not correlate with labo-
ratory parameters of systemic inﬂ  ammation (ESR and CRP).
Centre 2
FOI ﬁ  ndings were compared with clinical ﬁ  ndings in 1110 joints 
(244 tender, 261 swollen, 85 tender and swollen). FOI was com-
pared with GSUS and PDUS ﬁ  ndings of the clinically dominant 
hand in 962 joints. Four hundred and ﬁ  fty-three joints were posi-
tive in GSUS, 148 in PDUS and 136 in GSUS and PDUS (includ-
ing tenosynovitis). A total of 303 out of 522 (58%) clinically 
asymptomatic joints showed positive ﬁ  ndings in GSUS and 53 
out of 522 (10%) showed positive ﬁ  ndings in PDUS. FOI dis-
played positive ﬁ  ndings in 864 out of 1110 (78%) joints and in 
473 out of 615 (77%) clinically asymptomatic joints.
Sensitivity and speciﬁ  city
Taking GSUS as reference, CE had a sensitivity of 25% and a 
speciﬁ  city of 90% and FOI had a sensitivity of 70% and a spec-
iﬁ  city of 48%. With PDUS as reference, CE had a sensitivity 
of 43% and a speciﬁ  city of 88% and FOI had a sensitivity of 
74% and a speciﬁ  city of 42%. Speciﬁ  city of P1 and P3 were high 
(GSUS: 95% and 78%; PDUS: 90% and 69%) with correspond-
ing lower sensitivity (GSUS: 22% and 51%; PDUS: 33% and 
60%) (table 2).
Agreement rates
ARs of CE and GSUS ranged from 56% to 60%, ARs of CE and 
PDUS ranged from 76% to 84%, ARs of CE and FOI ranged 
Centre 1
FOI ﬁ  ndings were compared with clinical ﬁ  ndings in 750 joints 
(128 tender, 148 swollen, 83 swollen and tender). FOI was com-
pared with MRI ﬁ  ndings in 300 joints (ﬁ  gure 4). Fifty-nine joints 
showed MRI synovitis, and 75 joints showed synovitis or teno-
synovitis. MRI detected inﬂ  ammatory changes in 31 out of 194 
(16%) clinically asymptomatic joints. FOI displayed positive 
ﬁ  ndings in 387 out of 750 (77%) joints and in 250 out of 557 
(45%) clinically asymptomatic joints.
Sensitivity and speciﬁ  city
Taking MRI as the gold standard for inﬂ  ammatory  changes 
(synovitis or tenosynovitis), CE had a sensitivity of 53% and a 
speciﬁ  city of 81%. FOI had a sensitivity of 76% and a speciﬁ  city 
of 54%. Speciﬁ  city of phase 1 (P1) and phase 3 (P3) was high 
(94% and 89%), with corresponding low sensitivity (27% and 
47%) (table 2).
Agreement rates
AR of CE and MRI ranged from 63% to 87%, AR of CE and FOI 
ranged from 44% to 88% and AR of MRI and FOI ranged from 
48% to 88%, depending on the parameter and subgroup (tables 
3, 4, S1 and S2). The disagreement mainly resulted from the 
higher rate of positive ﬁ  ndings in FOI. The highest agreement 
was found for P1, and the lowest was found for phase 2 (P2).
Correlations of FOI with assessments of disease activity
FOI scores correlated signiﬁ   cantly and relevantly with the 
Rheumatoid Arthritis MRI Score (RAMRIS) (r=0.66, p<0.0001) 
Table 1  Demographic and clinical data of study population
  Diagnosis
RA (n=67) PsA (n=60) uA (n=74) Other (n=45)
χ  
_
 ±SD; median (range) χ −
 ±SD; median (range) χ
_
 ±SD; median (range) χ
_
 ±SD; median (range)
Age (years) 58±8.3 59 (28–84) 51±10 54 (26–79) 53±10 53 (14–74) 50±14 53 (16–83)
Gender (men/women) 17/52 19/32 18/75 13/43
Disease duration (months) 76±67 53 (2–420) 48±41 25 (0–360) 19±19 8 (0–180) 62±67 17 (0–456)
DAS28 (0–10)* 3.8±1.0 3.9 (0.8–6.3) 3.6±1.1 3.8 (0.0–6.7) 3.6±1.1 3.7 (1.0–6.0) – –
ESR (mm/h) 20±13 14 (1–100) 17±11 12 (2–87) 20±13 16 (1–72) 18±11 12 (1–68)
CRP (mg/dl) 0.5±0.5 0.2 (0.0–7.8) 0.4±0.4 0.3 (0.0–4.6) 0.5±0.5 0.2 (0.0–5.1) 0.5±0.4 0.1(0.0–4,4)
SJC (ﬁ  nger joints) 7±4 5 (3–16) 2±2 1 (0–6) 5±3 6 (0–10) 2±2 1 (0–11)
TJC (ﬁ  nger joints) 5±4 5 (0–12) 3±2 3 (0–14) 5±3 4 (0–11) 3±3 2 (0–10)
RAMRIS 4±3 2 (0–18) – – 2±1 1 (0–4) – –
RAMRIS synovitis 7±6 3 (0–28) – – 3±2 2 (0–14) – –
US score 58±1 49 (11–118) 27±1 25 (9–104) 29±13 27 (1–80) 17±9 13(2–82)
*DAS28 only calculated for RA, PsA and uA.
Other six healthy controls=six arthralgia being above suspicion of inﬂ  ammatory disease.
CRP, C reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RAMRIS, Rheumatoid Arthritis MRI 
Score; SJC, swollen joint count; TJC, tender joint count; uA, undifferentiated arthritis; US, ultrasonography.
Figure 2  FOI ﬁ  ndings in active rheumatoid arthritis (RA). Phase 1 (A) displays focal increases signal intensities until ﬁ  rst increased signals in 
ﬁ  ngertips (early enhancement phase), phase 2 (B) shows increased signal intensities at the same time as signals in ﬁ  ngertips (intermediate phase), 
and phase 3 (C) is reached after increased signal intensities of ﬁ  ngertips has decreased (late phase).
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Safety
In all subjects, the procedure was well tolerated. Adverse events 
were not observed.
DISCUSSION
ICG-enhanced FOI with the Xiralite system is a new imaging 
technology. To our knowledge, this is the ﬁ  rst study to evaluate 
the application in patients with arthritis and to compare it with 
CE, US and MRI.
We found that FOI agreed well with CE, MRI and US. FOI 
was more sensitive for detecting synovitis and tenosynovitis 
than CE. FOI showed a higher rate of positive ﬁ  ndings than 
the other compared modalities. In an FOI sequence, three 
phases could be distinguished, with different sensitivity and 
speciﬁ  city as well with different AR. FOI scores correlated 
signiﬁ  cantly with assessment of disease activity (DAS28, US 
score, RAMRIS). In healthy subjects, FOI was negative in 
almost all joints.
FOI relies on the ﬂ  uorescence optical detection of vascular-
ity in inﬂ  amed tissues by the means of ICG as a ﬂ  uorophor.23 24 
Angiogenesis is an early event and is highly dysregulated in 
inﬂ  ammatory disorders such as arthritis or psoriasis.25 In RA, 
hypervascularisation and angiogenesis of the synovial mem-
brane are considered to be primary pathogenic mechanisms 
responsible for the aggressiveness of the rheumatoid pannus 
on the joint and are suggested as the link to bone destruction.26 
Synovial vascularisation correlated with the disease activity of 
a given joint,27 28 with radiographic progression29 and with the 
therapeutic response in patients with RA.5
from 35% to 88%, ARs of GSUS and FOI ranged from 53% 
to 72% and ARs of PDUS and FOI ranged from 46% to 82%, 
depending on the parameter and subgroup (tables 3, 4, S1 and 
S3). The disagreement mainly resulted from the higher rate of 
positive ﬁ  ndings in FOI. The highest agreement was found for 
P1, and the lowest was found for P2.
Correlation of FOI with assessments of disease activity
FOI scores correlated signiﬁ  cantly and relevantly with DAS28 
(r=0.41, p<0.0001) and US (r=0.40, p=0.0008) but not with labo-
ratory parameters (ESR and CRP).
Subgroup analysis
Generally, the AR did not differ signiﬁ  cantly in RA, PsA or uA. 
Exceptions were the AR for FOI versus CE (s+t) in RA and uA 
(p=0.0309) and the AR of FOI and GSUS in RA compared to uA 
(p=0.0018) and PsA (p=0.0017, tables S2 and S3).
Control group
In 12 controls (6 healthy and 6 with arthralgia without any 
sign of inﬂ  ammatory rheumatic disease; median age 30 years, 
range 21–56 years, 3 women), 360 joints were evaluated. FOI 
did not detect any positive ﬁ  ndings in 97.8–100% of joints (ﬁ  gure 
S1), depending on the evaluated image or phase. FOI displayed 
positive ﬁ  ndings in 1 out of 360 joints (0.3%) in CI, 8 out of 
360 joints (2.2%, grade 1 changes) in P2 and none in P1 and P3. 
MRI was available in ﬁ  ve controls. While MRI was normal, FOI 
showed minimal changes in CI and P2 (1 out of 60 joints, 1.2%, 
and 2 out of 60 joints, 3.3%) and none in P1 and P3.
Figure 3  FOI (CI) and GSUS in psoriatic arthritis (PsA). FOI shows signal intensities in projection of the joints, tendons, osseous and periosteal 
structures corresponding to clinical dactylitis. Besides, triangular, slightly arcuate enhancements in projection of the nail bed in ﬁ  ngers 3 and 4 of the 
right hand are seen. GSUS presents an anechoic structure (*) around the hyperechoic ﬂ  exor tendon (t) corresponding to tenosynovitis. CI, composite 
image; FOI, ﬂ  uorescence optical imaging; GSUS, ultrasonography in greyscale mode; PsA, psoriatic arthritis.
Figure 4  Comparison of FOI (CI) and MRI ﬁ  ndings. Corresponding signal intensities in FOI and contrast-enhanced (gadolinium) MRI in PIP 2, 3, and 5 
of the left hand (A, B). CI, composite image; FOI, ﬂ  uorescence optical imaging.
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and 42%, respectively. A higher speciﬁ  city and a lower sensitiv-
ity were seen for P1 (GSUS 95% and 22%; PDUS 90% and 33%) 
and P3 (GSUS 78% and 51%; PDUS 69% and 60%). AR was 
up to 82% with PDUS. Thus, FOI displayed US synovitis and 
tenosynovitis reliably. Similar to MRI, the disagreement of FOI 
and US mainly resulted from the higher rate of positive ﬁ  ndings 
in FOI. FOI agreed in a higher range with PDUS, which also 
displays vascularity.
In a comparative study30 with MRI as reference, US revealed a 
sensitivity of 40–70% for synovitis and an agreement (73–100%) 
comparable to our ﬁ  ndings for FOI. Especially for the inﬂ  amma-
tory changes, the sensitivity and agreement of US were lower 
than those for destructive changes. Similar results were obtained 
in other studies.31 32 US and MRI display both morphological 
changes (eg, pannus, erosions) and dynamic changes (eg, hyper-
aemia, hypervascularity, hyperperfusion). FOI only displays 
the dynamic changes. Because of the broader range of dynamic 
changes compared to morphological changes, we strongly 
believe that interpretation of ﬁ  ndings is more difﬁ  cult and this 
may have an inﬂ  uence on sensitivity and AR.
Controls
In the control group, FOI was normal in 97.8% joints. None of 
the 360 joints was FOI positive in P1 or P3. Positive ﬁ  ndings 
were in low grade. This observation supports the interpretation 
that the disagreement of FOI with MRI and US in the majority 
of cases did not result from false-positive ﬁ  ndings.
Subgroups
AR did not differ signiﬁ  cantly between patients with RA, PsA 
and uA in most scenarios. Thus, this ﬁ  nding suggests that FOI 
is able to detect inﬂ  ammatory changes independently of the 
underlying disease.
In animal models, FOI has been shown as an appropriate 
method to identify inﬂ  ammatory changes in arthritic joints.15 29 
The histopathological ﬁ  ndings of these studies showed early 
inﬂ  ammatory changes in FOI-positive joints.
In the present study, FOI was compared to CE, MRI and 
US in two larger cohorts of patients with arthritis and in 
healthy controls. The major ﬁ  ndings were comparable in both 
centres.
FOI versus CE
FOI agreed well with clinically swollen and tender joints. 
Disagreement of FOI and CE mainly resulted from the higher 
rate of positive ﬁ  ndings in FOI. The highest agreement was seen 
for FOI P1 and swollen and tender joints, indicating that P1 dis-
plays joints with high clinical activity. With MRI or US as refer-
ence, FOI was more sensitive than CE.
FOI versus MRI
FOI agreed well with MRI synovitis and tenosynovitis. Taking 
MRI as reference, FOI had a sensitivity of 76% and a speciﬁ  c-
ity of 54%, with a higher speciﬁ  city (94% and 89%) and a 
lower sensitivity (27% and 47%) for P1 and P3, respectively. 
AR was up to 88%. Thus, FOI is able to detect MRI synovi-
tis and tenosynovitis reliably. Disagreement of FOI and MRI 
mainly resulted from the higher rate of positive ﬁ  ndings in FOI. 
A possible explanation is that the different imaging modali-
ties display distinct aspects of the underlying inﬂ  ammatory 
pathology. This hypothesis can be proven only by histological 
examinations.
FOI versus US
FOI agreed well with US. With GSUS or PDUS as reference, we 
found a sensitivity of 70% and 74% and a speciﬁ  city of 48% 
Table 2  Sensitivity and speciﬁ  city of FOI and CE versus PDUS, GSUS and MRI (synovitis or tenosynovitis) as standards of reference along with 95% 
conﬁ  dence intervals
FOI MRI S or T PDUS GSUS
Sensitivity Speciﬁ  city Sensitivity Speciﬁ  city Sensitivity Speciﬁ  city
FOI CI 51% (38/75) 81% (182/225) 67% (88/132) 54% (358/661) 56% (223/398) 57% (227/395)
41%; 60% 72%; 89% 58%; 76% 49%; 59% 50%; 62% 51%; 64%
FOI P1 27% (20/75) 94% (209/223) 33% (49/148) 90% (736/814) 22% (100/453) 95% (482/509)
10%; 43% 89%; 98% 21%; 45% 87%; 94% 15%; 29% 92%; 97%
FOI P2 72% (54/75) 56% (127/225) 72% (106/148) 44% (361/814) 68% (306/453) 50% (256/509)
63%; 81% 46%; 67% 62%; 81% 40%; 49% 62%; 73% 45%; 56%
FOI P3 47% (35/75) 89% (201/225) 60% (89/148) 69% (561/814) 51% (229/453) 78% (396/509)
36%; 58% 83%; 95% 50%; 71% 63%; 75% 43%; 58% 72%; 84%
Any phase (P1–P3) 76% (57/75) 54% (122/225) 74% (110/148) 42% (340/814) 70% (318/453) 48% (243/509)
67%; 85% 43%; 65% 65%; 84% 37%; 47% 64%; 76% 42%; 53%
CE 53% (39%; 67%) 81% (76%; 87%) 43% (31%; 54%) 88% (83%; 92%) 25% (18%; 31%) 90% (86%; 94%)
Any phase, positive in any phase; CE, clinical examination (swollen joints); CI, composite image; FOI, ﬂ  uorescence optical imaging; GSUS, ultrasonography in greyscale mode; 
P1, phase 1; P2, phase 2; P3, phase 3; PDUS, ultrasonography in power Doppler mode; S, synovitis; T, tenosynovitis.
Table 3  ARs of ﬂ  uorescence optical imaging with CE, MRI and US
CE s (%) CE t (%) CE s+t (%)
  C1 C2 C1 C2 C1 C2 MRI S (%) MRI T (%) MRI S/T (%)  GSUS (%) PDUS (%)
FOI CI 72 46 71 44 73 44 73 74 73 58 46
FOI P1 79 82 80 80 84 88 78 83 77 60 82
FOI P2 58 48 58 46 56 46 59 54 60 58 48
FOI P3 78 70 77 66 81 70 79 79 79 64 68
More detailed tables S1, S2 and S3 including 95% CI are only available online.
AR, agreement rate; c1, centre 1; c2, centre 2; CE, clinical examination; CI, composite image; FOI, ﬂ  uorescence optical imaging; GSUS, ultrasonography in greyscale mode; 
P1, phase 1; P2, phase 2; P3, phase 3; PDUS, ultrasonography in power Doppler mode; s, swollen joints; S, synovitis; t, tender joints; T, tenosynovitis.
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Table 4  ARs of CE with MRI, US and ﬂ  uorescence optical imaging
  MRI S (%) MRI T (%) MRI S or T (%) GSUS (%) PDUS (%)
FOI CI (%) FOI P1 (%) FOI P2 (%) FOI P3 (%)
C1 C2 C1 C2 C1 C2 C1 C2
CE s 76 76 74 60 80 72 46 79 82 58 48 78 70
CE t 75 76 71 56 76 71 44 80 80 58 46 77 66
CE s+t 81 83 77 56 84 73 88 84 88 56 46 81 70
More detailed tables S1, S2 and S3 including 95% CI are only available online.
AR, agreement rate; C1, centre 1; C2, centre 2; CE, clinical examination; CI, composite image; FOI, ﬂ  uorescence optical imaging; GSUS, ultrasonography in greyscale mode; P1, 
phase 1; P2, phase 2; P3, phase 3; PDUS, ultrasonography in power Doppler mode; s, swollen joints; S, synovitis; t, tender joints; T, tenosynovitis.
Phases
AR of FOI and CE, MRI and US differed for the CI and the 
phases. FOI P1 showed the highest agreement with CE and 
PDUS, which suggests that P1 displays high local disease activ-
ity with high vascularity. The speciﬁ  city of P1 and P3 was high. 
Thus, ﬁ  ndings in these phases seem to be of special interest. 
The highest sensitivity was seen in P2 and is comparable to the 
sensitivity of US with MRI as reference reported from other 
studies.30 32 While the meaning of the phases is still unclear, an 
adequate interpretation of an FOI exam requires a speciﬁ  c read-
ing of all the phases.
Subclinical inﬂ  ammation
MRI, GSUS and PDUS showed positive ﬁ  ndings in 16%, 58% 
and 10% of clinically asymptomatic joints, respectively. This 
is in alignment with results of other studies where MRI and 
US detected a higher rate of affected joints than CE.3 30–32 In 
our study, FOI showed positive ﬁ  ndings in 45% of clinically 
asymptomatic joints, indicating that FOI also detects subclinical 
inﬂ  ammation.
Differential diagnostic aspects
A characteristic pattern of signal distribution was seen in patients 
with PsA. The morphological aspect indicates an association 
with the synovio-entheseal complex.33 This sign may provide 
additional information for differential diagnosis but has to be 
validated with a larger number of patients.
Correlations with scores of disease activity
We found that FOI correlated signiﬁ  cantly with disease activ-
ity scores (DAS28, US score, RAMRIS). Monitoring of disease 
activity and valid assessment of remission, the special target for 
RA treatment,1 are a crucial aspect with respect to the rapidly 
growing armamentarium of disease-modifying drugs. Our data 
indicate that FOI may be an additional tool for the assessment of 
disease activity in arthritic conditions.
Limitations
We are aware of some limitations concerning the image inter-
pretation and quantiﬁ  cation of pathological changes. While the 
examination procedure itself has been standardised in detail, 
consistent standards for image adjustment and interpretation 
are not yet established. In this study, we have chosen a semi-
quantitative evaluation of FOI ﬁ  ndings, comparable to US image 
interpretation. Generally, the digital technology of the Xiralite 
system allows an automatic image interpretation and quantita-
tive analysis of image sequences, but appropriate software is not 
yet available. With a substantial34 intrareader (κ=0.73) and inter-
reader (κ=0.73) agreement (separate study, data not published), 
our method of image interpretation seems to be reliable.
In conclusion, ICG-enhanced FOI with the Xiralite system 
is a new imaging technology that allows a sensitive and valid 
assessment of inﬂ  ammation in arthritis. FOI was comparable 
to 1.5 T MRI and US in detecting synovitis and tenosynovitis. 
Thereby, it is a fast and safe imaging screening tool for patients 
with suspected arthritis. Furthermore, FOI is useful for objec-
tifying treatment response and treatment monitoring. FOI was 
more sensitive than CE. In addition, FOI could be helpful in 
the differentiation of nail involvement and arthritis of DIPs in 
patients with psoriasis and/or PsA. However, further investiga-
tions are needed for a comprehensive deﬁ  nition of FOI patholo-
gies, advancement of methodical standards and evaluation of 
sensitivity to change and prognostic value.
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